Cargando…
Designing an evidence-based Bayesian network for estimating the risk versus benefits of AstraZeneca COVID-19 vaccine
Uncertainty surrounding the risk of developing and dying from Thrombosis and Thrombocytopenia Syndrome (TTS) associated with the AstraZeneca (AZ) COVID-19 vaccine may contribute to vaccine hesitancy. A model is urgently needed to combine and effectively communicate evidence on the risks versus benef...
Autores principales: | Mayfield, Helen J., Lau, Colleen L., Sinclair, Jane E., Brown, Samuel J., Baird, Andrew, Litt, John, Vuorinen, Aapeli, Short, Kirsty R., Waller, Michael, Mengersen, Kerrie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989774/ https://www.ncbi.nlm.nih.gov/pubmed/35450781 http://dx.doi.org/10.1016/j.vaccine.2022.04.004 |
Ejemplares similares
-
Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network modelling framework
por: Lau, Colleen L., et al.
Publicado: (2021) -
Risk-benefit of AstraZeneca COVID-19 vaccination in Australia
Publicado: (2021) -
AstraZeneca COVID-19 vaccine: thrombosis with thrombocytopenia
Publicado: (2021) -
Anaphylaxis in Australia with AstraZeneca's COVID-19 vaccine
Publicado: (2021) -
Vaccin Oxford/AstraZeneca, mode d’emploi
por: Dalmat, Yann-Mickael
Publicado: (2021)